Acorda Therapeutics (ACOR)
Acorda Therapeutics Key Statistics
Pro Data ExportCurrent Valuation
| Market Cap | 894.84M |
| Enterprise Value | 844.81M |
| PE Ratio | 23.24 |
| PE 10 Pro | Go Pro |
| PEG Ratio | 0.0722 |
| Price / Sales Ratio | 2.961 |
| Price / Book Value | 4.084 |
| EV / Revenues Pro | Go Pro |
| EV / EBITDA Pro | Go Pro |
| EV / EBIT Pro | Go Pro |
| Operating Earnings Yield Pro | Go Pro |
Dividends and Shares
| Dividend | |
| Dividend Yield | 0.00% |
| Cash Div. Payout Ratio TTM Pro | Go Pro |
| Payout Ratio TTM Pro | Go Pro |
| Dividend Date | |
| Ex-Dividend Date | |
| Last Split Factor | |
| Last Split Date |
Profitability
| Gross Profit Margin | 82.28% |
| EBITDA Margin TTM Pro | Go Pro |
| Operating Margin TTM Pro | Go Pro |
| Profit Margin | 11.01% |
Management Effectiveness
Liquidity and Solvency
| Altman Z-Score Pro | Go Pro |
| Current Ratio | 4.238 |
| Debt to Equity Ratio | 0.0241 |
| KZ Index Pro | Go Pro |
| Tangible Common Equity Ratio Pro | Go Pro |
| Times Interest Earned TTM Pro | Go Pro |
Stock Price Performance
| Beta Pro | Go Pro |
| 1 Month Stock Returns | -10.16% |
| Year to Date Stock Returns | -5.45% |
| 1 Year Stock Returns | -31.68% |
| 3 Year Stock Returns | -9.37% |
| 52 Week High | 33.48 |
| 52 Week Low | 18.36 |
Income Statement
| Revenues TTM | 302.20M |
| Revenue Per Share TTM | 7.612 |
| Revenue Growth | 16.25% |
| Gross Profit TTM | 235.22M |
| EBITDA TTM Pro | Go Pro |
| Income from Cont. Ops Pro | Go Pro |
| Net Income TTM | 39.12M |
| Earnings Per Share TTM | 0.97 |
| Other Comprehensive Income Pro | Go Pro |
Cash Flow Statement
| Cash Investing TTM | -108.21M |
| Cash Financing TTM | 3.583M |
| Cash Operations TTM | 81.47M |
| Capital Expenditures | 3.104M |
Share Statistics
| Shares Outstanding | 39.70M |
Balance Sheet
| Cash and ST Investments | 278.55M |
| Total Assets | 386.05M |
| Liabilities | 166.96M |
| Book Value | 219.09M |
| Book Value per Share | 5.519 |
| Tangible Book Value Pro | Go Pro |
| Tangible Book Value Per Share Pro | Go Pro |
| Long Term Debt | 4.126M |
Earnings Quality
| Accruals Pro | Go Pro |
| Beneish M-Score Pro | Go Pro |
You may also be interested in these ACOR related companies
ACOR News
Pre-Open Movers 5/18: (PSUN) (WGO) (CRM) Higher; (ADSK) (SQNM) (ARUN) Lower (more...)
May 18, 9:28AM Street Insider
May 18, 9:28AM Street Insider
News related to $ACOR, currently -1.1% since open: 'Alkermes takes bigger 4Q loss after Elan deal' http://stks.co/3sPL
about 10 days ago by TradeBot
about 10 days ago by TradeBot
2012 Economic Outlook - Report Highlights Acorda Therapeutics Inc and Pharmacyclics, Inc.
May 17, 9:00AM Marketwire
May 17, 9:00AM Marketwire
Listen to $ACOR Q1 2012 earnings call - live at 08:30 AM, ondemand after - http://stks.co/3e2R
about 24 days ago by earningscast
about 24 days ago by earningscast
Acorda Therapeutics Recognized as One of the Best Places to Work in New York State for Second Consecutive Year
Apr 30, 7:00AM Business Wire
Apr 30, 7:00AM Business Wire
Acorda Therapeutics to Host Conference Call to Discuss First Quarter 2012 Financial Results on May 3, 2012
Apr 26, 6:00AM Business Wire
Apr 26, 6:00AM Business Wire
Listen to $ACOR Acorda Therapeutics, Inc. Research & Development Conf Call - live at 10:00 AM, ondemand after - http://stks.co/3NSr
about 40 days ago by earningscast
about 40 days ago by earningscast
Acorda Therapeutics Named One of the 100 Most Trustworthy Companies by Forbes
Apr 12, 7:00AM Business Wire
Apr 12, 7:00AM Business Wire
$ACOR my biotech stock is back!!!! What happened here up another buck!
about 72 days ago by HTB_Krull
about 72 days ago by HTB_Krull
Acorda Therapeutics to Present at the Cowen & Company 32nd Annual Health Care Conference
Feb 27, 7:30AM Business Wire
Feb 27, 7:30AM Business Wire
Acorda Therapeutics to Present at 2012 RBC Capital Markets' Global Healthcare Conference
Feb 22, 6:00AM Business Wire
Feb 22, 6:00AM Business Wire
Acorda Therapeutics to Present at Citi 2012 Global Health Care Conference
Feb 21, 6:00AM Business Wire
Feb 21, 6:00AM Business Wire
Citi Downgrades Acorda Therapeutics, Inc. (ACOR) to Neutral, Raises Price Target to $29
Feb 17, 7:36AM Street Insider
Feb 17, 7:36AM Street Insider
Big earnings beat for $acor, but the market is not too excited yet. It has 6 days of short interest, so it is one to watch if it gets going
about 101 days ago by ivanhoff
about 101 days ago by ivanhoff
Listen to $ACOR Q4 2011 earnings call (EPS 0.45 vs est 0.18) - live at 08:30 AM, ondemand after - http://stks.co/2RDb
about 101 days ago by earningscast
about 101 days ago by earningscast
Listen to $ACOR Acorda Therapeutics, Inc. at Biotechnology Industry Organization - live at 01:00 PM, ondemand after - http://stks.co/2Opp
about 103 days ago by earningscast
about 103 days ago by earningscast
$ACOR may be flashing pocket pivot today as it rebounds from its 50-day line in above average volume. Strong fundamentals. Good accumulation
about 104 days ago by JeanPaul
about 104 days ago by JeanPaul
BIO CEO Conference Live Blog. http://stks.co/2N3g $ONTY $KERX $GILD $CYCC $IDIX $CHTP $ACOR
about 104 days ago by abubnic
about 104 days ago by abubnic
$REGN is one just started shorting since hitting near $102 mon, little scalps have netted a few pts , has ER next wk with $ACOR & $NPSP
about 109 days ago by ronin245
about 109 days ago by ronin245
Recent Quotes
| Symbol | Price | Chg | Chg % | Market Cap |
|---|---|---|---|---|
| ACOR | 22.54 | -0.12 | -0.53% | 894.84M |
| ACOM | 21.88 | +0.09 | +0.41% | 937.78M |
| ACO | 29.03 | -0.83 | -2.78% | 924.90M |
| ACN | 57.44 | -0.55 | -0.95% | 37.18B |
| ACM | 16.69 | +0.06 | +0.36% | 1.955B |
| ACLS | 1.12 | +0.11 | +10.89% | 120.00M |
| ACIW | 40.03 | -0.07 | -0.17% | 1.568B |
| ACI | 7.23 | -0.07 | -0.96% | 1.533B |
| ACHN | 7.35 | +0.03 | +0.41% | 518.69M |
| ABB | 16.18 | -0.22 | -1.34% | 37.45B |
